EORTC CLTF 2018 | Pembrolizumab trial shows promising responses in cutaneous lymphoma

Michael Khodadoust

Michael Khodadoust, MD, PhD, of the Stanford University School of Medicine, Stanford, CA, speaks at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland. Dr Khodadoust discusses the CITN-10 trial (NCT02243579), which investigated the use of pembrolizumab in relapsed/refractory mycosis fungoides or Sézary syndrome. He highlights the patient response rates and a uniquesideeffect that was observed in the Sézary population.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter